ESMO 2022: Summary of ESMO Adjuvant RCC Trials


Axel Bex summarizes the RCC studies that were presented at ESMO 2022, including potential toxicity of ipilimumab/nivolumab, pembrolizumab response rates, and single-agent atezolizumab versus placebo.

Related Episodes

Episode 196: The COSMIC-313 Trial Cabo/Ipi/Nivo in First-Line Renal Cancer
ESMO 2022: Enfortumab Vedotin Plus Pembrolizumab Versus Pembrolizumab Alone for Urothelial Carcinoma
ESMO 2022: Breaking Down the Phase 3 PIVOT-09 Study
ESMO 2022: PRESTO – A Phase 3 Androgen Annihilation in Biochemically Relapsed Prostate Cancer
ESMO 2022: PROSPER Study of Neoadjuvant Nivolumab in RCC
Episode 190: ESMO 2022 Overview